Jeff Johnson

Stock Analyst at Baird

(4.66)
# 200
Out of 5,146 analysts
154
Total ratings
59.05%
Success rate
28.9%
Average return

Stocks Rated by Jeff Johnson

Henry Schein
Feb 23, 2026
Upgrades: Outperform
Price Target: $78$100
Current: $81.91
Upside: +22.09%
Beta Bionics
Feb 18, 2026
Maintains: Neutral
Price Target: $28$14
Current: $12.89
Upside: +8.61%
Tandem Diabetes Care
Dec 16, 2025
Upgrades: Outperform
Price Target: $18$30
Current: $26.01
Upside: +15.34%
Zimmer Biomet Holdings
Dec 16, 2025
Downgrades: Neutral
Price Target: $117$100
Current: $99.85
Upside: +0.15%
The Cooper Companies
Dec 5, 2025
Maintains: Outperform
Price Target: $85$98
Current: $83.47
Upside: +17.41%
Alcon
Nov 13, 2025
Maintains: Outperform
Price Target: $95$98
Current: $86.27
Upside: +13.60%
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112$90
Current: $73.16
Upside: +23.02%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21$23
Current: $29.59
Upside: -22.27%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378$405
Current: $384.03
Upside: +5.46%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325$276
Current: $188.05
Upside: +46.77%
Upgrades: Outperform
Price Target: $180$238
Current: $248.12
Upside: -4.08%
Maintains: Outperform
Price Target: $67$70
Current: $22.32
Upside: +213.62%
Maintains: Outperform
Price Target: $53$61
Current: $13.96
Upside: +336.96%
Maintains: Outperform
Price Target: $78$67
Current: $12.80
Upside: +423.44%